Matches in SemOpenAlex for { <https://semopenalex.org/work/W2955647079> ?p ?o ?g. }
Showing items 1 to 67 of
67
with 100 items per page.
- W2955647079 endingPage "S353" @default.
- W2955647079 startingPage "S353" @default.
- W2955647079 abstract "To compare and contrast the structures and cost-effectiveness results for two different modeling approaches in advanced COPD. The analyses each compared once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/25μg with twice-daily budesonide/formoterol (BUD/FOR) 400/12μg, based on the FULFIL trial (NCT02345161) outcomes. Two different model structures were reviewed: a linked risk equation model (GALAXY, Zhang et al. VIH 2017) versus a two-part model, combining a decision tree for the trial period with a Markov model for long-term extrapolation (Fenwick et al. VIH 2018). Incorporation of treatment effects, costs of events and clinical status, utility weights, survival projections, model findings and assessments of uncertainty were compared. The two models differ in the method of estimating declining lung function and risk of exacerbation among the model cohort, including differences in the links between exacerbation and marginal lung function decline. Differences were noted in the costing structure and assignment of utility decrements. Both models included separate handling of moderate and severe exacerbations and discontinuation parameters; however, only the two-part model included pneumonia events. Despite differing approaches, both models showed FF/UMEC/VI as cost-effective compared with BUD/FOR (with incremental costs, incremental QALY, and incremental cost-effectiveness ratios [ICER]; of £1,652, 0.49, and £3,357/QALY gained for the GALAXY model, and £677, 0.50, and £1,325/QALY gained for the two-part model). Both models included probabilistic analyses varying risk prediction and treatment effect inputs and scenario testing of trial subgroup efficacy; conclusion of neither model were significantly impacted by uncertainty. Despite differences in the model structures and the handling of treatment effect inputs, the two models provided similar results and demonstrated the cost-effectiveness of FF/UMEC/VI compared with BUD/FOR. It further supports the robust results of the FULFIL trial. Additional considerations regarding availability of market-specific data may impact model selection in future adaptation and submission work." @default.
- W2955647079 created "2019-07-12" @default.
- W2955647079 creator A5019669640 @default.
- W2955647079 creator A5026383766 @default.
- W2955647079 creator A5031372755 @default.
- W2955647079 creator A5035698459 @default.
- W2955647079 creator A5063127845 @default.
- W2955647079 creator A5067651492 @default.
- W2955647079 date "2019-05-01" @default.
- W2955647079 modified "2023-10-18" @default.
- W2955647079 title "PRS24 COMPARISON OF TWO ECONOMIC MODELS IN THE EVALUATION OF THE COST-EFFECTIVENESS OF TRIPLE THERAPY TREATMENT FOR ADVANCED CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)" @default.
- W2955647079 doi "https://doi.org/10.1016/j.jval.2019.04.1728" @default.
- W2955647079 hasPublicationYear "2019" @default.
- W2955647079 type Work @default.
- W2955647079 sameAs 2955647079 @default.
- W2955647079 citedByCount "1" @default.
- W2955647079 countsByYear W29556470792021 @default.
- W2955647079 crossrefType "journal-article" @default.
- W2955647079 hasAuthorship W2955647079A5019669640 @default.
- W2955647079 hasAuthorship W2955647079A5026383766 @default.
- W2955647079 hasAuthorship W2955647079A5031372755 @default.
- W2955647079 hasAuthorship W2955647079A5035698459 @default.
- W2955647079 hasAuthorship W2955647079A5063127845 @default.
- W2955647079 hasAuthorship W2955647079A5067651492 @default.
- W2955647079 hasBestOaLocation W29556470791 @default.
- W2955647079 hasConcept C112930515 @default.
- W2955647079 hasConcept C126322002 @default.
- W2955647079 hasConcept C26831200 @default.
- W2955647079 hasConcept C2776042228 @default.
- W2955647079 hasConcept C2776780178 @default.
- W2955647079 hasConcept C2777014857 @default.
- W2955647079 hasConcept C2778715236 @default.
- W2955647079 hasConcept C2779028295 @default.
- W2955647079 hasConcept C3019080777 @default.
- W2955647079 hasConcept C44249647 @default.
- W2955647079 hasConcept C71924100 @default.
- W2955647079 hasConceptScore W2955647079C112930515 @default.
- W2955647079 hasConceptScore W2955647079C126322002 @default.
- W2955647079 hasConceptScore W2955647079C26831200 @default.
- W2955647079 hasConceptScore W2955647079C2776042228 @default.
- W2955647079 hasConceptScore W2955647079C2776780178 @default.
- W2955647079 hasConceptScore W2955647079C2777014857 @default.
- W2955647079 hasConceptScore W2955647079C2778715236 @default.
- W2955647079 hasConceptScore W2955647079C2779028295 @default.
- W2955647079 hasConceptScore W2955647079C3019080777 @default.
- W2955647079 hasConceptScore W2955647079C44249647 @default.
- W2955647079 hasConceptScore W2955647079C71924100 @default.
- W2955647079 hasLocation W29556470791 @default.
- W2955647079 hasOpenAccess W2955647079 @default.
- W2955647079 hasPrimaryLocation W29556470791 @default.
- W2955647079 hasRelatedWork W176029630 @default.
- W2955647079 hasRelatedWork W2058227331 @default.
- W2955647079 hasRelatedWork W2075905701 @default.
- W2955647079 hasRelatedWork W2380657675 @default.
- W2955647079 hasRelatedWork W2621503191 @default.
- W2955647079 hasRelatedWork W2766467225 @default.
- W2955647079 hasRelatedWork W2885268879 @default.
- W2955647079 hasRelatedWork W2909257760 @default.
- W2955647079 hasRelatedWork W3020850777 @default.
- W2955647079 hasRelatedWork W4237479062 @default.
- W2955647079 hasVolume "22" @default.
- W2955647079 isParatext "false" @default.
- W2955647079 isRetracted "false" @default.
- W2955647079 magId "2955647079" @default.
- W2955647079 workType "article" @default.